Navigation Links
EuroDYNA takes lid off the genome
Date:6/13/2008

sms, from bacteria to eukarya. PRR was discovered in the 1970s, but here again the detailed mechanisms are only now being elicited. At the EuroDYNA conference, Simone Sabbioneda from the University of Sussex presented new findings about one of the key PRR mechanisms called Translesion DNA Synthesis (TLS). This project, like some of the others, involved direct observation of processes as they take place in living cells, in this case using a technique called Fluorescence Recovery after Photobleaching. This comprises an optical microscope combined with a probe to observe the radiation emitted (the fluorescence) by molecules within a cell in response to a laser source. Such work is yielding important clues on how the PRR pathways work, hoping to help in the long term campaign to find novel, more specific, treatments for cancer, without the side effects of current therapies based on surgery, radiotherapy, or chemotherapy.

One EuroDYNA project however yielded a more immediate insight into a treatment already used to alleviate the symptoms of another important disease, MS (multiple sclerosis). Pavel Kovarik from the University of Vienna's Department of Microbiology and Immunology noted that the only compound capable of alleviating MS symptoms was the protein interferon beta. This resembles the interferon produced naturally by the body in response to infection, but until now it has not been known how it relieves symptoms for MS sufferers. However Kovarik and colleagues have shown that interferon works by upregulating (increasing production of) members of the protein family Tristetraprolin (TTP), which have an anti-inflammatory affect by in turn inhibiting production of pro-inflammatory agents. "We have demonstrated a novel function for interferon," said Kovarik. By understanding how it works, there is the potential for delivering interferon beta more effectively for treating MS.

There were other projects within EuroDYNA with great therapeutic potential,
'/>"/>

Contact: Astrid Lunkes
alunkes@esf.org
33-388-762-172
European Science Foundation
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Frog study takes leaf out of natures book
2. Researchers discover critical detail of cellular defense against genetic mistakes
3. Unravelling new complexity in the genome
4. Conquest of land began in shark genome
5. One species entire genome discovered inside anothers
6. Genome study shines light on genetic link to height
7. First individual genome sequence published
8. Ultraconserved elements in the genome: Are they indispensable?
9. $10 million gift to support cutting-edge epigenome center at USC
10. Fungus genome yielding answers to protect grains, people and animals
11. Which came first, the chicken genome or the egg genome?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... today in Science , researchers from Cambridge, Glasgow ... in how transcription factors, the proteins that bind to ... function over large evolutionary distances. The text books ... they regulate by binding to short, sequence-specific lengths of ...
... reef ecosystems are highly valued for their diverse ... reef fishing and tourism industries, but they are ... over-exploitation. The National Institute for Mathematical ... for its Investigative Workshop, Modeling Reef Ecosystems, to ...
... info@engconfintl.org ) and the Cell Culture Engineering ... proud to announce Prof. Michael J. Betenbaugh, ... Culture Engineering Award.,Mike Betenbaugh ( http://www.jhu.edu/chembe/faculty-template/MichaelBetenbaugh.html ) ... at Johns Hopkins University, Baltimore, MD, USA. ...
Cached Biology News:Rewiring of gene regulation across 300 million years of evolution 2Michael Betenbaugh wins 2010 Cell Culture Engineering award 2
(Date:5/1/2015)... /CNW/ - Softchoice, a leading North American IT solutions and managed ... of two Cisco® Partner Summit Country awards. ... Security Partner of the Year for Canada ... in Montreal . "We ... awards at this year,s conference," said David MacDonald , ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... -- Oxford Finance LLC ("Oxford"), a specialty finance firm ... services companies, today announced the closing of a $10 ... a diagnostic testing company focused on improving the accuracy ... improved outcomes.  Proceeds of the loan will be used ... its products in the U.S. and China ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Oxford Finance Provides $10 Million Debt Financing to Celula 2
... at American Society of Clinical Oncology , , ... presented data demonstrating the use of ChemoFX(R), a chemosensitivity ... the colorectal cancer cells of individual patients. Results ... colorectal cultures tested, eight percent were responsive to cetuximab, ...
... KVISTGAARD, Denmark, June 1 Detailed ... Saturday at the,ASCO Annual Meeting in Orlando. The presentation was ... School , and the Dana-Farber Cancer,Institute who is also the ... The more detailed analysis supports the headline data that were ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung ... Clinical Oncology (ASCO) annual meeting. The meeting is being held ... , The presentation, entitled "A Phase II Study of Intravenous ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 2PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 3
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... TYPE II Reacts with most of ... cell keratin of 86 and 58kD and ... keratin reactivity is found on human epidermal ... Immunogen: Human epidermal cells ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Biology Products: